Osteosarcoma (OS) is a highly aggressive primary bone cancer with a particularly poor prognosis in metastatic cases, and treatment continues to face significant challenges due to tumor heterogeneity, immune resistance, and an unfavorable tumor microenvironment (TME) (1). Despite important advancements in molecular biology, immunotherapy, and metabolic interventions, the treatment of OS remains difficult, requiring further research to optimize targeted therapies and improve immunotherapy and metabolic strategies. This review aims to explore the latest advancements in OS research, focusing on molecular targets, immunotherapy, metabolic reprogramming, and clinical trial strategies. Studies have shown that key signaling pathways, such as Wnt/β-catenin and mesenchymal-epithelial transition (MET), play crucial roles in OS progression, particularly in the activation at the tumor-stroma interface and the overexpression of the MET receptor. Emerging biomarkers like apo-transcobalamin-II (APO-TCN2) and death receptor 5 (DR5) have been identified, offering potential prognostic value. Additionally, chimeric antigen receptor T-cell (CAR-T) therapy and combination immunotherapies show promise in overcoming immune evasion mechanisms. Metabolic reprogramming, particularly through long non-coding RNA regulation (lncRNA) of glycolysis, provides new therapeutic targets for OS. Clinical research also highlights the importance of global participation in clinical trials, with the EuroSarcoma Network’s RECOGNIZE study demonstrating the feasibility and necessity of global participation to improve accessibility to new treatments. Despite these advancements, the treatment of OS remains challenging, and future research should continue to focus on optimizing targeted therapies, refining immunotherapeutic and metabolic interventions, improving early detection methods, integrating precision medicine, and innovating clinical trial designs to effectively translate research findings into better outcomes, ultimately improving the prognosis and quality of life for OS patients.A recent focus of research has been on the Wnt/β-catenin signaling pathway, which plays a significant role in OS progression. Its activation at the tumor-stroma interface has been shown to facilitate tumor development (Ding and Chen, 2025). Additionally, MET, a receptor for hepatocyte growth factor (HGF), is overexpressed in OS and associated with poor prognosis (Zeng et al., 2024). Targeting MET has shown therapeutic potential, and ongoing studies aim to explore combination therapies targeting both MET and other key pathways. Furthermore, novel biomarkers such as APO-TCN2 (Lacinski et al., 2024) and DR5 (Gamie et al., 2024) have been identified, with proteomic and transcriptomic studies indicating their correlation with improved overall survival in OS and other sarcomas. Research should focus on further exploring the interactions between Wnt/β-catenin and other signaling pathways, validating APO-TCN2 and DR5 as biomarkers for early detection, developing more specific MET inhibitors, and investigating combination therapies that could improve treatment outcomes in OS. Moreover, understanding the crosstalk between these pathways and their influence on immune cell recruitment presents new opportunities for therapeutic interventions. Recent advances in single-cell RNA sequencing (scRNA-seq) have enabled a more detailed exploration of TME, providing insights into how immune cells interact with tumor cells and surrounding stromal components, which can help identify novel therapeutic targets (2). Additionally, combining CRISPR-Cas9 gene editing technology with nanoparticle drug delivery systems allows for precise manipulation of immune responses and targeted gene editing of immune evasion mechanisms, presenting new avenues for treatment. By modulating immune cell recruitment and activation within the TME, these strategies aim to enhance the efficacy of immunotherapies and offer potential improvements in the treatment of OS and other cancers (3). These approaches hold promise for personalized therapy tailored to the unique immune landscape of each patient.In recent years, immunotherapy has shown promise in treating various cancers, but its efficacy in OS remains limited due to the complexity of the TME. Immune evasion mechanisms, such as the inactivation of phosphatase and tensin homolog deleted on chromosome 10 (PTEN), lead to hyperactivation of the PI3K-AKT pathway, which significantly reduces the effectiveness of immunotherapies (4). The tumor cells in OS employ multiple mechanisms to evade immune detection, making single-agent therapies ineffective. Therefore, combination therapies aimed at overcoming tumor heterogeneity and immune evasion mechanisms are being actively researched. Fourth-generation CAR-T cell therapies, which utilize co-expression of CXC chemokine receptor 5 (CXCR5) and interleukin (IL)-7, have demonstrated preclinical efficacy (3). One study showed that the co-expression of CXCR5 and IL-7 significantly enhanced CAR-T cell effectiveness by improving tumor penetration, persistence, and cytotoxicity (Hui et al., 2024). Additionally, a bibliometric analysis of immunotherapy research for OS highlights China’s role as a leader in this field, with significant trends pointing toward increasing interest in the TME, immune checkpoint inhibitors, and CAR-T cell therapy (Hu et al., 2025).The TME plays an integral role in OS metastasis. Recent studies have shown that neutrophil plasticity influences tumor progression, with the N1 subset exhibiting tumoricidal effects and the N2 subset supporting premetastatic niche formation (5). Targeting these neutrophil subsets could offer a novel strategy to prevent metastasis (Xia et al., 2024). Moreover, metabolic reprogramming, particularly the enhancement of the Warburg effect in OS tumor cells, presents new therapeutic opportunities. Modulating metabolic pathways to inhibit OS cell growth and migration has become an area of intense research (Zeng et al., 2024). lncRNAC1QTNF1-AS1 has been shown to regulate glycolysis through miR-34a-5p, promoting tumor growth and metastasis (Zhang et al., 2025). Targeting these metabolic pathways, especially glycolysis, may provide new therapeutic strategies to treat OS.One of the major challenges in OS research is the limited representation of pediatric populations in clinical trials. Efforts to establish decentralized clinical trial networks, such as the EuroSarcoma Network’s RECOGNIZE study, have proven that global participation is not only feasible but also critical for ensuring equitable access to new therapies. These efforts can serve as a model for future trials aiming to enhance diversity and ensure that all patient populations benefit from treatment advancements (Hu et al., 2025). In addition, a clinical case report describes a rare occurrence of costal chondrosarcoma secondary to multiple hereditary exostoses (HME), which compressed the right ventricle. The patient underwent intralesional resection followed by adjuvant radiotherapy, with no recurrence observed during the one-year follow-up. This case highlights the importance of early imaging screening and multidisciplinary management in patients with HME to improve diagnostic accuracy, optimize treatment strategies, and reduce the risk of recurrence (Yang et al., 2025).As research in molecular biology and immunology progresses,OS treatment is entering an innovative phase. Future studies should prioritize precision medicine and individualized treatment plans, with a particular focus on integrating immunotherapy and metabolic interventions. Further exploration of lncRNA-miRNA interactions in OS is essential to identify new therapeutic targets, particularly those involving glycolytic enzymes (Zhang et al., 2025). A review of competing endogenous RNA (ceRNA) mechanisms in cancer underscores the importance of ceRNA interactions in cancer biology, which could open new avenues for targeted therapy (6). Additionally, addressing immune resistance mechanisms and tumor resistance will be crucial in advancing OS treatment. Enhancing early screening methods for detecting malignant transformations in HME and refining treatment protocols for rare conditions such as costal chondrosarcoma will also be essential. The focus should be on translating these innovations into clinical practice to improve patient outcomes and inform personalized therapeutic approaches. By fostering interdisciplinary collaboration and embracing novel strategies, OS treatment outcomes can be significantly improved, ultimately offering patients better prognoses and quality of life. Integrating multi-omics data—such as genomics, proteomics, and metabolomics—provides a deeper understanding of tumor heterogeneity and the molecular basis of osteosarcoma, facilitating the development of precision medicine strategies tailored to individual patients (2). These omics-guided approaches can reveal actionable mutations, dysregulated signaling pathways, and metabolic vulnerabilities, enabling clinicians to select therapies that are more likely to be effective while minimizing unnecessary toxicity. This systems-level approach holds transformative potential for OS management (1,7).This Research Topic underscores the importance of innovative, interdisciplinary approaches in overcoming the current limitations of OS treatment. The integration of novel therapeutic strategies, including targeted metabolic interventions, advances in immunotherapy, and TME modulation, offers new hope for improving patient outcomes. Moreover, addressing structural barriers to clinical trial design—particularly by enhancing global participation and equity—is crucial for ensuring these innovations benefit all affected populations.
Editorial08 April 2025
Editorial: Therapeutic mechanism of osteosarcomaREVIEW
14 February 2025
Osteosarcoma (OS) is the most common bone malignancy in children and adolescents, and although current neoadjuvant chemotherapy has shown efficacy against OS, the long-term survival rate for patients with OS remains low, highlighting the need to find more effective treatments. In cancer cells, abnormal activation of signaling pathways can widely affect cell activity from growth and proliferation to apoptosis, invasion and metastasis. Wnt/β-catenin is a complex and unique signaling pathway that is considered to be one of the most important carcinogenic pathways in human cancer. Research have confirmed that the Wnt/β-catenin signaling pathway is an important driving factor for the occurrence and development of osteosarcoma, and abnormal activation of this pathway can promote the pathological processes of cell proliferation, invasion, migration, tumor angiogenesis and chemical resistance of osteosarcoma. However, inhibition of Wnt/β-catenin signaling pathway can effectively inhibit or reverse the above pathological processes. Therefore, manipulating the expression or function of the Wnt/β-catenin pathway may be a potential targeted pathway for the treatment of OS. In this review, we describe the characteristics of the Wnt/β-catenin signaling pathway and summarize the role and mechanism of this pathway in OS. This paper discusses the therapeutic significance of inhibiting or targeting Wnt/β-catenin pathway in OS and the shortcomings of current studies on this pathway in OS and the problems to be solved. This review helps us to understand the role of Wnt/β-catenin on OS, and provides a theoretical basis and new ideas for targeting Wnt/β-catenin pathway as a therapeutic target for OS.
SYSTEMATIC REVIEW
10 February 2025
Yunxiang Hu, 2 more and Zefeng Song
4 Authors
- YH
Yunxiang Hu
Department of Orthopaedic Trauma, The Second Affiliated Hospital of Dalian Medical University, China
- RY
Rui Yang
School of Graduates, Dalian Medical University, China
- SN
Shuai Ni
Department of Orthopaedic Trauma, The Second Affiliated Hospital of Dalian Medical University, China
- ZS
Zefeng Song
School of Graduates, Dalian University of Technology, China
ObjectiveThe objective of this study is to conduct a bibliometric analysis on examining the current condition, areas of interest, and rising trends of immunotherapy for osteosarcoma (ITFOS), as well as its importance in associated research domains.MethodsAn extensive collection of academic papers on the use of ITFOS was obtained from the Web of Science between January 1, 2000 and October 20, 2023. Then, using a variety of tools like HisCite, VOSviewer, CiteSpace, and the bibliometrix package, a bibliometric study was carried out. This study included the collection of information on country, institution, author, journal, and keywords.ResultsA comprehensive analysis was undertaken on a total of 616 publications obtained from 247 journals, encompassing the contributions of 3725 authors affiliated with 831 institutes spanning across 43 countries/regions. Notably, China exhibited the highest quantity of published 277 (44.99%) articles on ITFOS. The most productive institution was Zhejiang University, with 26 (4.22%) publications. The author with the highest publication output was Tsukahara, Tomohide from Japan with 15 (2.44%) publications. The article with the most citation was “DOI: 10.1200/JCO.2014.58.0225”. Frontiers in Immunology demonstrated the highest level of productivity, having published a total of 31 (5.03%) articles. The most frequently used were “osteosarcoma,” “immunotherapy,” and “cancer,”. Meanwhile, “sequencing”, “prognostic signature” and “immune microenvironment“ have been identified as the research frontiers for the forthcoming years.ConclusionThis paper provides a thorough evaluation of current research trends and advancements in ITFOS. It includes relevant research findings and emphasizes collaborative efforts among authors, institutions, and countries.
Solid tumors are characterized by a low blood supply, complex stromal architecture, and immunosuppressive milieu, which inhibit CAR-T cell entry and survival. CXCR5 has previously been employed to increase CAR-T cell infiltration into CXCL13+ cancers. On the other hand, IL-7 improves the survival and persistence of T cells inside a solid tumor milieu. We constructed a novel NKG2Dbased CAR (C5/IL7-CAR) that co-expressed CXCR5 and IL-7. The human osteosarcoma cell lines U-2 OS, 143B, and Mg63 highly expressed MICA/B and CXCL13, thus presenting a perfect avenue for the present study. Novel CAR-T cells are superior in their activation, degranulation, and cytokine release competence, hence lysing more target cells than conventional CAR. Furthermore, CXCR5 and IL-7 co-expression decreased the expression of PD-1, TIM-3, and TIGIT and increased Bcl-2 expression. Novel CAR-T cells show enhanced proliferation and differentiation towards the stem cell memory T cell phenotype. C5/IL7-CAR-T cells outperformed conventional CAR-T in eradicating osteosarcoma in mouse models and displayed better survival. Additionally, CXCR5 and IL-7 coexpression enhanced CAR-T cell numbers, cytokine release, and survival in implanted tumor tissues compared to conventional CAR-T cells. Mechanistically, C5/IL7-CAR-T cells displayed enhanced STAT5 signaling. These findings highlight the potential of CXCR5 and IL-7 co-expression to improve CAR-T cell therapy efficacy against osteosarcoma.
Background: Death Receptor (DR) 5 is expressed on the surface of primary bone and soft tissue sarcoma cells and its activation induces cell death primarily through apoptosis.Combination of DR5 agonists with commonly used chemotherapeutic agents such as doxorubicin can promote cell death. Presently clinical trials are investigating the effectiveness of DR5 activation using new biological agents such as bi-specific or tetravalent antibodies in improving the survival of patients with relapsed or refractory cancers. Furthermore, investigations continue into the use of novel combination therapies for enhancing DR5 response, for example, with Inhibitor of Apoptosis Protein (IAP) antagonist agents [such as second mitochondria-derived activator of caspase (smac) mimetics] and with immune checkpoint inhibitor anti-programmed death-ligand 1 (anti-PD-L1) or antiprogrammed cell death 1 (anti-PD-1) antibody. Other therapies include nanoparticlemediated delivery of TRAIL plasmid DNA or TRAIL mRNA and stem cells as a vehicle for the targeted delivery of anti-cancer agents such as TRAIL to the tumour. Methods: Scoping review of the literature from November 2017 to March 2024 utilising PubMed and Google Scholar. Results: New agents under investigation include NanoTRAIL, anti kv10.1, Multimeric IgM and humanised tetravalent antibodies. Developments have been made to test novel agents and imaging has been used to detect DR5 in preclinical models and patients. The models include 3D spheroids, genetically modified mouse models, a novel jaw osteosarcoma model and patient-derived PDX animal models. There are currently two ongoing clinical trials focussing on the activation of DR5, namely, IGM-8444 and INBRX-109, which have progressed to phase 2. Further modifications of TRAIL delivery with fusion to single-chain variable fragments (scFv-TRAIL), directed against tumour-associated antigens (TAA) and in the use of stem cells focus on targeted TRAIL delivery to cancer cells using bi-functional strategies. Conclusion: In vitro, in vivo and clinical trials as well as advances in imaging and theranostics indicate that targeting DR5 remains a valid strategy in the treatment of some relapsed and refractory cancers.




